Загрузка...

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia

Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thromboc...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Haematol
Главные авторы: Jurczak, Wojciech, Chojnowski, Krzysztof, Mayer, Jiří, Krawczyk, Katarzyna, Jamieson, Brian D., Tian, Wei, Allen, Lee F.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282556/
https://ncbi.nlm.nih.gov/pubmed/30191972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15573
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!